Evaluation of Xueshuantong in Patients With AcutE IschemiC STroke
Status:
Recruiting
Trial end date:
2023-05-31
Target enrollment:
Participant gender:
Summary
The aim is to assess the effects and harms of Xueshuantong lyophilized powder versus placebo
in patients with acute ischemic stroke when initiated within 72 hours of symptom onset.
Phase:
Phase 4
Details
Lead Sponsor:
Dongzhimen Hospital, Beijing
Collaborator:
Tianjin University of Traditional Chinese Medicine